J N Rich

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint The cancer stem cell: a new therapeutic paradigm?
    Jeremy N Rich
    Expert Rev Anticancer Ther 6:1531-3. 2006
  2. ncbi request reprint Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines
    J N Rich
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 274:35053-8. 1999
  3. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
  4. ncbi request reprint Development of novel targeted therapies in the treatment of malignant glioma
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Rev Drug Discov 3:430-46. 2004
  5. ncbi request reprint Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Drugs Today (Barc) 42:657-70. 2006
  6. ncbi request reprint Cancer stem cells in radiation resistance
    Jeremy N Rich
    Department of Medicine, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 67:8980-4. 2007
  7. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
  8. ncbi request reprint Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Biol Chem 278:15951-7. 2003
  9. ncbi request reprint The role of transforming growth factor-beta in primary brain tumors
    Jeremy N Rich
    Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 8:e245-60. 2003
  10. ncbi request reprint Gene expression profiling and genetic markers in glioblastoma survival
    Jeremy N Rich
    Department of Medicine, W M Keck Center for Neuro Oncogenomics, Institute of Statistics and Decision Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:4051-8. 2005

Research Grants

Collaborators

Detail Information

Publications74

  1. ncbi request reprint The cancer stem cell: a new therapeutic paradigm?
    Jeremy N Rich
    Expert Rev Anticancer Ther 6:1531-3. 2006
  2. ncbi request reprint Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines
    J N Rich
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 274:35053-8. 1999
    ..This suggests that the loss of p15(INK4B) may explain, in part, the selective loss of growth inhibition by TGF-beta in gliomas to form a more aggressive tumor phenotype...
  3. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  4. ncbi request reprint Development of novel targeted therapies in the treatment of malignant glioma
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Rev Drug Discov 3:430-46. 2004
  5. ncbi request reprint Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Drugs Today (Barc) 42:657-70. 2006
    ..Phase II studies in other cancers have likewise been initiated. This review summarizes preclinical and clinical studies of vandetanib for the treatment of cancers...
  6. ncbi request reprint Cancer stem cells in radiation resistance
    Jeremy N Rich
    Department of Medicine, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 67:8980-4. 2007
    ..Hypoxia and stem cell maintenance pathways may provide therapeutic targets to sensitize cancer stem cells to cytotoxic therapies to improve cancer patient treatments...
  7. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  8. ncbi request reprint Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Biol Chem 278:15951-7. 2003
    ..Genetically defined human cancer models offer useful tools in functional genomics to define the roles of specific genes in late stages of carcinogenesis...
  9. ncbi request reprint The role of transforming growth factor-beta in primary brain tumors
    Jeremy N Rich
    Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 8:e245-60. 2003
    ..Early preclinical and clinical studies have shown promise of anti-TGF-beta strategies in the treatment of malignant gliomas suggesting TGF-beta may be a potential new therapeutic target in neuro-oncology...
  10. ncbi request reprint Gene expression profiling and genetic markers in glioblastoma survival
    Jeremy N Rich
    Department of Medicine, W M Keck Center for Neuro Oncogenomics, Institute of Statistics and Decision Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:4051-8. 2005
    ....
  11. doi request reprint Chemotherapy and cancer stem cells
    Jeremy N Rich
    Department of Medicine, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Cell Stem Cell 1:353-5. 2007
    ..In this issue of Cell Stem Cell, Todaro et al. (2007) demonstrate that targeting tumor IL-4 sensitizes colon cancer stem cells to chemotherapy...
  12. ncbi request reprint A genetically tractable model of human glioma formation
    J N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 61:3556-60. 2001
    ..This model system will, for the first time, allow the biological significance of selected genetic alterations to be studied in human gliomas...
  13. ncbi request reprint Antiangiogenic therapy in malignant glioma: promise and challenge
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Pharm Des 13:3545-58. 2007
    ..In this review, we will discuss the current development, promise and challenge of antiangiogenic therapy in malignant glioma...
  14. pmc Brain cancer stem cells display preferential sensitivity to Akt inhibition
    Christine E Eyler
    School of Medicine, Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham North Carolina, USA
    Stem Cells 26:3027-36. 2008
    ..Together, these results suggest that Akt inhibitors may function as effective anticancer stem cell therapies...
  15. pmc c-Myc is required for maintenance of glioma cancer stem cells
    Jialiang Wang
    Department of Surgery, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e3769. 2008
    ..As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells...
  16. doi request reprint Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  17. ncbi request reprint Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Shideng Bao
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nature 444:756-60. 2006
    ..Targeting DNA damage checkpoint response in cancer stem cells may overcome this radioresistance and provide a therapeutic model for malignant brain cancers...
  18. pmc NDRG4 is required for cell cycle progression and survival in glioblastoma cells
    Stephen H Schilling
    Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 284:25160-9. 2009
    ..Collectively, these data indicate that NDRG4 is required for cell cycle progression and survival, thereby diverging in function from its tumor suppressive family member NDRG2 in astrocytes and GBM cells...
  19. pmc Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:501-13. 2009
    ..Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies...
  20. pmc Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
    Br J Cancer 107:1481-7. 2012
    ..We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries...
  21. ncbi request reprint Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
    Chris A Learn
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 10:3216-24. 2004
    ..Determination of how this differential inhibition occurs may be important to patient selection and treatment criteria, as well as the design of future therapeutics for glioblastoma multiforme...
  22. pmc Targeting cancer stem cells through L1CAM suppresses glioma growth
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 68:6043-8. 2008
    ....
  23. pmc Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis
    Christine E Eyler
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, PO Box 2900, Durham, NC 27710, USA
    J Clin Oncol 26:2839-45. 2008
    ..Identifying and targeting the molecular mechanisms responsible for CSC therapeutic resistance may improve the efficacy of current cancer therapies...
  24. pmc Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth
    Hui Wang
    Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, USA
    Stem Cells 27:2393-404. 2009
    ..Together, our data indicate that IL6 signaling contributes to glioma malignancy through the promotion of GSC growth and survival, and that targeting IL6 may offer benefit for glioma patients...
  25. ncbi request reprint A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth
    Qing Shi
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Carcinog 46:488-96. 2007
    ..TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy...
  26. ncbi request reprint Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases
    Q Shi
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Oncogene 26:4084-94. 2007
    ..These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers...
  27. ncbi request reprint Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    H S Friedman
    Departments of Surgery, Medicine, Pathology, Radiology, and Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 18:3522-8. 2000
    ..We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity and maximum-tolerated dose (MTD) of BCNU in conjunction with the preadministration of O(6)-BG with recurrent or progressive malignant glioma...
  28. ncbi request reprint New approaches to primary brain tumor treatment
    Sith Sathornsumetee
    Departments of Medicine, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Anticancer Drugs 17:1003-16. 2006
    ..It is probable, however, that targeted therapies will be most effective in combination either with one another or with cytotoxic therapies. In this study, we review the current state of new therapies for malignant gliomas...
  29. doi request reprint Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    ..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated...
  30. pmc Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Michael A Badruddoja
    Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 9:70-4. 2007
    ..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme...
  31. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  32. ncbi request reprint The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
    Anita B Hjelmeland
    Department of Surgery, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 6:2449-57. 2007
    ..These data suggest that the combination of LBT613 and RAD001 reduces glioma cell proliferation and invasion and support examination of the combination of RAF and TOR inhibitors for the treatment of human glioblastoma patients...
  33. ncbi request reprint SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility
    Mark D Hjelmeland
    Division of Neurology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 3:737-45. 2004
    ..Together, our results suggest that small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility...
  34. ncbi request reprint Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity
    Anita B Hjelmeland
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 65:11276-81. 2005
    ..Thus, the loss of PTEN expression in human cancers may contribute to a role for TGF-beta as a tumor enhancer with specific effects on cellular motility and invasion...
  35. ncbi request reprint Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:7843-8. 2006
    ..Together these data indicate that stem cell-like tumor cells can be a crucial source of key angiogenic factors in cancers and that targeting proangiogenic factors from stem cell-like tumor populations may be critical for patient therapy...
  36. ncbi request reprint Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation
    Qing Shi
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 279:52200-9. 2004
    ..As tumor cells face stressful microenvironments particularly during the process of invasion, these results suggest that SPARC functions, in part, to promote tumor progression by enabling tumor cells to survive under stressful conditions...
  37. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  38. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  39. pmc Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 284:16705-9. 2009
    ..In this minireview, we summarize recent data regarding critical signaling pathways involved in brain tumor stem cell biology and discuss how targeting these molecules may contribute to the development of novel anti-glioma therapies...
  40. ncbi request reprint Diagnosis and treatment of high-grade astrocytoma
    Sith Sathornsumetee
    Division of Neurology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA
    Neurol Clin 25:1111-39, x. 2007
    ..It is probable that targeted therapies will be most effective in combination with one another or with cytotoxic therapies. This article discusses diagnosis and current treatment of high-grade astrocytomas...
  41. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  42. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  43. pmc Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 10:330-40. 2008
    ..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population...
  44. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  45. pmc Notch promotes radioresistance of glioma stem cells
    Jialiang Wang
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Stem Cells 28:17-28. 2010
    ..Taken together, our results suggest a critical role of Notch signaling to regulate radioresistance of glioma stem cells. Inhibition of Notch signaling holds promise to improve the efficiency of current radiotherapy in glioma treatment...
  46. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  47. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  48. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  49. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  50. doi request reprint The emerging role of anti-angiogenic therapy for malignant glioma
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Curr Treat Options Oncol 9:1-22. 2008
    ..Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy...
  51. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  52. ncbi request reprint Recent advances in the treatment of malignant astrocytoma
    David A Reardon
    Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:1253-65. 2006
    ..The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival...
  53. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  54. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  55. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  56. ncbi request reprint Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 103:329-38. 2005
    ..In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease...
  57. ncbi request reprint Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1478-86. 2005
    ..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)...
  58. ncbi request reprint Chemotherapy and novel therapeutic approaches in malignant glioma
    Annick Desjardins
    The Brain Tumor Center, Department of Pediatrics, Duke University Medical Center, 047 Baker House, Trent Drive, Box 3624, Durham, NC 27710, USA
    Front Biosci 10:2645-68. 2005
    ..In this article, we review the past, present and future treatments of malignant gliomas with a special interest on chemotherapy, resistance mechanisms and tyrosine kinase inhibitors...
  59. ncbi request reprint New treatment strategies for malignant gliomas
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center Division of Neurosurgery Neuro Oncology, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 6:1087-104. 2006
    ..Predictive biomarkers will enrich for patients most likely to respond in future clinical trials. Additional clinical studies will combine novel targeted therapies with radiation, chemotherapies and immunotherapies...
  60. ncbi request reprint AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  61. pmc Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:145-53. 2004
    ....
  62. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  63. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
    ..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma...
  64. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  65. pmc Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:134-44. 2004
    ..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic...
  66. pmc Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology
    Michael T Forrester
    Department of Biochemistry, Medical Scientist Training Program, Duke University Medical Center, Durham, NC 27710, USA
    Biotechniques 50:41-5. 2011
    ..This technique boosts endogenous cellular consumption of NO, thus providing a simple and efficacious approach to studying mammalian NO biology that can be employed as both a primary experimental and confirmatory tool...
  67. pmc Distinct requirements for Ras oncogenesis in human versus mouse cells
    Nesrin M Hamad
    Department of Pharmacology, Division of Neurology, Duke University Medical Center, Durham North Carolina 27710, USA
    Genes Dev 16:2045-57. 2002
    ..Thus, oncogenic Ras may transform murine and human cells by distinct mechanisms, and the RalGEF pathway--previously deemed to play a secondary role in Ras transformation--could represent a new target for anti-cancer therapy...
  68. pmc Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
    S Gururangan
    Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 3:246-50. 2001
    ..Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days...
  69. ncbi request reprint Molecularly targeted therapy for malignant glioma
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 110:13-24. 2007
    ..In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma...
  70. ncbi request reprint Neurofibromatosis type 2
    S Sathornsumetee
    Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neurology 68:E14. 2007
  71. doi request reprint Hypoxia and hypoxia inducible factors in cancer stem cell maintenance
    Zhizhong Li
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Curr Top Microbiol Immunol 345:21-30. 2010
    ..These findings illustrated a new mechanism through which oxygen tension and microenvironment influences cancer development. Targeting hypoxia niches may therefore improve therapy efficacy by eliminating cancer stem cell population...
  72. ncbi request reprint Making a tumour's bed: glioblastoma stem cells and the vascular niche
    Richard J Gilbertson
    Department of Developmental Neurobiology and Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA
    Nat Rev Cancer 7:733-6. 2007
    ..These data have direct implications for cancer, highlighting the similarity between normal and malignant stem cells and identifying the tumour microenvironment as a target for new therapies...
  73. ncbi request reprint Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway
    Shideng Bao
    The Key Laboratory for Cell Biology and Tumor Cell Engineering, The Ministry of Education of China, The School of Life Sciences, Xiamen University, Fujian 361005, China
    Cancer Cell 5:329-39. 2004
    ..These data demonstrated that the survival-promoting function is crucial for periostin to promote tumor metastasis of colon cancer...
  74. ncbi request reprint EGFR mutations and sensitivity to gefitinib
    Jeremy N Rich
    N Engl J Med 351:1260-1; author reply 1260-1. 2004

Research Grants5

  1. TGF BETA AND BRAIN TUMORS
    Jeremy Rich; Fiscal Year: 2002
    ....
  2. Molecular Mechanisms of SPARC Mediated Glioma Invasion
    Jeremy Rich; Fiscal Year: 2007
    ..These studies will contribute to the understanding of the regulation of glioma invasion and provide the basis of novel targeted therapies for gliomas. ..
  3. The Roles of Osteonectin and Osteoactivin in Gliomas
    Jeremy Rich; Fiscal Year: 2007
    ..2) Validate osteonectin and osteoactivin as potential therapeutic targets in glioma invasion. It is hoped that these studies will provide the basis of novel therapeutic interventions for patients with malignant gliomas. ..
  4. TGFbeta-PTEN Interactions in Glioma Biology & Therapy
    Jeremy Rich; Fiscal Year: 2007
    ..Any promising new therapies can be directly translated into clinical trials at the Preston Robert Tisch Brain Tumor Center. ..